BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cytognos, S.L. - ECPv4.9.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cytognos, S.L.
X-ORIGINAL-URL:https://www.cytognos.com
X-WR-CALDESC:Events for Cytognos, S.L.
BEGIN:VTIMEZONE
TZID:"Europe/Paris"
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210330
DTEND;VALUE=DATE:20210331
DTSTAMP:20260316T063413
CREATED:20210316T112246Z
LAST-MODIFIED:20210318T115336Z
UID:16586-1617062400-1617148799@www.cytognos.com
SUMMARY:Webinar - Experience with MM MRD in our clinical laboratory: theory and practice – 5 PM GMT
DESCRIPTION:The level of minimal residual disease (MRD) is paramount to link the depth of response and long-term outcome. Recent advances in treatment demand a more sensitive response criteria which includes MRD evaluation. Therefore\, MRD has been defined as one of the best surrogate markers to predict overall survival and accelerate the approval of new therapies in Multiple Myeloma (MM). \nIn this webinar\, Mantas Radzevičius will explain: \n\nTheoretical basis and clinical use of MRD evaluation\nHow to implement standard guidelines in a clinical flow cytometry laboratory\nMM MRD sample requirements and how to determine sample adequacy\nMM MRD consensus antibody panel\nManual and automatic analysis – pitfalls and difficulties in analysis\nMM MRD report – relevant clinical information\n\nMantas Radzevičius works at Vilnius University Hospital Santaros Klinikos\, in the Hematology and General Cytology laboratory\, as a laboratory medicine physician. He performs flow cytometry assays in patients with hematological conditions including leukemia/lymphoma\, multiple myeloma\, PNH and MDS. Mantas cooperates with international organizations such as ESCCA and NOPHO. His PhD project is focused on the interaction between tumour cells and their immune microenvironment\, as well as expression of immune checkpoint molecules. \n7 PM GMT+2 (Madrid\, Spain)\n8 PM GMT+3 (Vilnius\, Lithuania)\n1 AM GMT+8 (Beijing\, China)\n4 AM GMT +11 (Sydney\, Australia)\n2 PM GMT-3 (Rio de Janeiro\, Brasil)\n1 PM GMT-4 (New York\, NY\, USA)\n10 AM GMT-7 (Los Angeles\, CA\, USA) \n.fusion-button.button-1 .fusion-button-text\, .fusion-button.button-1 i {color:#bb0000;}.fusion-button.button-1 {border-width:1px;border-color:#bb0000;}.fusion-button.button-1 .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-1:hover .fusion-button-text\, .fusion-button.button-1:hover i\,.fusion-button.button-1:focus .fusion-button-text\, .fusion-button.button-1:focus i\,.fusion-button.button-1:active .fusion-button-text\, .fusion-button.button-1:active{color:#bb0000;}.fusion-button.button-1:hover\, .fusion-button.button-1:focus\, .fusion-button.button-1:active{border-width:1px;border-color:#bb0000;}.fusion-button.button-1:hover .fusion-button-icon-divider\, .fusion-button.button-1:hover .fusion-button-icon-divider\, .fusion-button.button-1:active .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-1 .fusion-button-text {text-transform:uppercase;}.fusion-button.button-1{width:auto;}Check your local time \n \n \n
URL:https://www.cytognos.com/event/webinar-experience-with-mm-mrd-in-our-clinical-laboratory-theory-and-practice-5-pm-gmt/
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/jpeg:https://www.cytognos.com/wp-content/uploads/webinar-MantasRadze-min.jpg
END:VEVENT
END:VCALENDAR